In all, 106 individuals satisfied our study inclusion criteria of being part of the chain of transmission within TTSH.
To be eligible for inclusion, studies had to satisfy our definition of a pharmacogenetic study: a study in which the response (intended outcome/adverse reaction) to drug therapy was examined in relation to genetic variation (germline/somatic) in humans.
However, many of these studies did not satisfy our stringent third criterion requiring at least two X Y ordered pairs.
Contact with experts in the field of pediatric T2D yielded two additional manuscripts, but upon review, these studies did not satisfy our inclusion criteria.
A total of 294 spontaneous term singleton, 15 spontaneous preterm singleton and 11 twin pregnancies which satisfied our criteria were studied.
After having read the abstracts, we selected 34 articles to read in full, of those we included 5 studies because these studies satisfied our inclusion criterion [ 14, 18].
In addition, no qualitative study satisfied our inclusion criteria.
Ultimately, seven studies satisfied our inclusion criteria [ 19, 23– 28], and a total of 17 eligible case-control studies consisting of nine studies [ 19, 23– 28] for the XbaI polymorphism containing 757 cases and 827 controls and eight studies [ 19, 23, 25– 28] for the PvuII polymorphism containing 651 cases and 747 controls were obtained from these publications.
All DCE properties were satisfied in our study.
Therefore, the well-designed nanocarriers for drug delivery should have a surface charge either slightly positive or slightly negative for long-term circulation in the blood stream, which requirement being well satisfied by our study results [ 39].
